Objective: To determine if persistent ovarian masses in pregnancy are associated with increased adverse outcomes.
Methods: This is a retrospective cohort of 126 pregnant women with a persistent ovarian mass measuring 5 cm or greater who delivered at two university hospitals between 2001 and 2009. Maternal outcomes included gestational age (GA) at diagnosis, delivery and surgery as well as miscarriage, preterm birth (PTB), ovarian torsion and hospital admission for pain. Neonatal outcomes included birth weight, respiratory distress syndrome (RDS), intra-ventricular hemorrhage (IVH), death and sepsis.
Results: A total of 1225 ovarian masses were identified (4.9%) in 24,868 patients. A persistent ovarian mass was found in 0.7%. Average GA at diagnosis was 17.8 weeks. Miscarriage rate was 3.3%. Average GA at delivery was 37.9 weeks. Of the patients, 8.5% had ovarian torsion, 10.3% had admission for pain and 9.3% had PTBs. The mean cesarean delivery rate was 46.3%. The average neonatal weight was 3273 g. There was one neonatal death in this cohort. The rate of RDS was 2.8%, IVH 0.9% and neonatal sepsis 1.9%. The most common surgical pathologic diagnosis was dermoids (37.6%). No overt malignancies were seen.
Conclusion: A persistent ovarian mass in pregnancy does not confer an increased risk of adverse pregnancy outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/14767058.2013.768980 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fertility in transgender and gender diverse people: systematic review of the effects of gender-affirming hormones on reproductive organs and fertility.
Hum Reprod Update
January 2025
Amsterdam UMC, Location Vrije Universiteit Amsterdam, Centre of Expertise on Gender Dysphoria, Amsterdam, The Netherlands.
Background: Transgender and gender diverse (TGD) people seek gender-affirming care at any age to manage gender identities or expressions that differ from their birth gender. Gender-affirming hormone treatment (GAHT) and gender-affirming surgery may alter reproductive function and/or anatomy, limiting future reproductive options to varying degrees, if individuals desire to either give birth or become a biological parent.
Objective And Rationale: TGD people increasingly pursue help for their reproductive questions, including fertility, fertility preservation, active desire for children, and future options.
Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines.
Vaccines (Basel)
January 2025
Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing 400030, China.
Human papillomavirus (HPV) is a major global health issue and is recognized as the leading cause of cervical cancer. While prophylactic vaccination programs have led to substantial reductions in both HPV infection rates and cervical cancer incidence, considerable burdens of HPV-related diseases persist, particularly in developing countries with inadequate vaccine coverage and uptake. The development of therapeutic vaccines for HPV represents an emerging strategy that has the potential to bolster the fight against cervical cancer.
View Article and Find Full Text PDFChanging trends in the global burden of polycystic ovarian syndrome-related infertility over the past 30 years: retrospective data analysis of the global burden of disease study 2019.
BMC Womens Health
January 2025
Reproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou City, Gansu, 730000, China.
Objectives: Polycystic ovary syndrome (PCOS) represents a significant and persistent metabolic disorder, emerging as a leading factor contributing to infertility. Despite its profound impact, there remains an inadequate understanding of the global burden of PCOS-related infertility across diverse regions and countries. The aim of this study was to evaluate the global, regional, and national burden of PCOS-related infertility from 1990 to 2019.
View Article and Find Full Text PDFUsing a Composite Summary of Daily Sex Hormones to Gauge Time Until Menopause: A Focus on Pregnanediol Glucuronide (PDG).
J Clin Endocrinol Metab
January 2025
Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Context: The timing of a woman's final menstrual period (FMP) in relation to her age is considered a valuable indicator of overall health, being associated with cardiovascular, bone health, reproductive, and general mortality outcomes.
Objective: This work aimed to evaluate the relationship between hormones and the "time to FMP" when daily hormone trajectories are characterized by their 1) entropy, and 2) deviation from premenopausal/stable cycle patterns (representing a textbook "gold standard"; GS).
Methods: As part of the Study of Women's Health Across the Nation, urinary luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen conjugates (E1C), and pregnanediol glucuronide (PDG) were measured daily from a multiracial sample of 549 mid-life women for the duration of one menstrual cycle.
Persistent Menorrhagia and Hemorrhagic Ovarian Cyst in a Patient With Bernard-Soulier Syndrome: A Case Report.
Cureus
December 2024
Hematology, Dubai Hospital, Dubai Health, Dubai, ARE.
Bernard-Soulier syndrome (BSS) is a rare qualitative condition of platelets wherein deficiency of platelet surface glycoproteins (GP) Ib, IX, and V forms the Ib-IX-V complex, leading to impaired hemostasis. Although it commonly presents as prolonged bleeding in general, women in the reproductive phase report additional complications during menstruation, pregnancy, and childbirth. In women of reproductive age, menorrhagia is a frequent complaint.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!